Rhythm Pharmaceuticals Inc.
NASDAQ:RYTM 3:59:52 PM EDT
Rhythm Pharmaceuticals Submits Supplemental NDA To U.S. FDA For IMCIVREE For Treatment Of Obesity In Bardet-Biedl And Alström Syndromes
Published: 09/20/2021 12:04 GMT
Rhythm Pharmaceuticals Inc. (RYTM) - Rhythm Pharmaceuticals Completes Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for Imcivree® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-biedl and AlstrÖm Syndromes.